<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C3843697-EACF-4836-9052-44E6043B606D"><gtr:id>C3843697-EACF-4836-9052-44E6043B606D</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Armitage</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12026%2F5"><gtr:id>C3137183-7F42-4F53-8504-968FE00AB6B1</gtr:id><gtr:title>Randomized trials in cardiovascular and metabolic diseases</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12026/5</gtr:grantReference><gtr:abstractText>The aim of this programme is to demonstrate reliably any benefits of treatments that can be widely used in common diseases such as heart disease, diabetes, stroke and cancer. Even quite modest improvements in outcome in common conditions can lead to important benefits for patients. In order to be sure that treatments really work, large numbers of people usually need to be given the treatment and compared with similar people not given the treatment. The most reliable way to do this is using randomisation, a method whereby who gets given a treatment is determined by chance (like tossing a coin). These randomised trials also often involve masking (or blinding) the treatment so that neither the participants nor their doctors or nurses know if they are taking an active or dummy treatment, this helps with making the study reliable. Over the past several years, we have pioneered ways of running randomised trials involving thousands of people efficiently and cost-effectively to gain reliable information. We have developed a wide experience of using IT and centrally held health records to streamline the running of large trials. Partly why statin treatments are so widely used is as a result of studies that we have run. Ongoing studies include testing aspirin in people with diabetes and a new lipid changing drug added to statin therapy in people at high risk of heart problems.</gtr:abstractText><gtr:technicalSummary>The aim of this programme is to generate reliable evidence about interventions with the potential for significant public health benefit. Treatments with even modest effects in common diseases (such as cancer, cardiovascular disease, diabetes, chronic kidney disease or osteoporosis) may make significant contributions to reducing morbidity and mortality globally. Building on epidemiological evidence generated in PHRU and elsewhere for associations between various biomarkers or risk factors (e.g. lipid markers, 25(OH) vitamin D), we aim to deliver large-scale randomised evidence to determine whether such associations are causal and reversible. Along with smoking and blood pressure, blood lipids are a major cause of cardiovascular disease, a major cause of morbidity and mortality worldwide. Higher levels of LDL cholesterol and lower levels of HDL cholesterol are associated with higher risks of coronary heart disease. Partly as a result of a series of large randomised trials (HPS, SEARCH and SHARP run by PHRU) and meta-analyses (also conducted by PHRU), statins, which effectively lower LDL cholesterol, are now very widely used for the primary and secondary prevention of cardiovascular disease. However, although widely used, available and highly cost-effective some patients remain at high risk despite statin use, thus additional safe treatments to modify risk are needed. Attention is now turning to newer drugs which modulate lipids by other mechanisms. The effects of such additional treatments on top of statins are likely to be modest, so large-scale randomised evidence are required to assess their effects reliably, hence the REVEAL trial of a cholesterol ester transfer protein inhibitor (CETPI) anacetrapib has randomized 30,000 people worldwide at risk of cardiovascular disease. 
Over the last several years, PHRU has developed streamlined methods to recruit large numbers of patients and conduct trials efficiently (e.g. REVEAL) as well as cost-effectively (e.g. ASCEND), including using factorial designs to address more than one question at a time and using record linkage to facilitate follow-up, both during the trials (e.g. ASCEND, 3C, LENS) and in the longer-term (e.g. HPS, SEARCH). In addition, PHRU has piloted trials of non-commercial questions (e.g. high-dose vitamin D in older people) and of a combination of angiotensin receptor blocker and neprolysin inhibitor (ARNI) in chronic kidney disease with a view to securing funding for larger trials aiming to generate reliable evidence.
Dementia and other neurodegenerative diseases are also major causes of public health problems, and incur huge costs for families and health and social services, but they have been relatively poorly researched. Collaborating with other researchers, MADE and Schizophrenia ATLAS in neurodegenerative diseases will help answer important clinical questions and help build collaborations for the future.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-07-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>852722</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>66400B0C-32A8-45D7-935C-755CC2898C68</gtr:id><gtr:title>Should We Increase GFR with Bardoxolone in Alport Syndrome?</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5aa004df3df8a2.80867913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3398E1CD-71E0-4082-9F31-66C9683BC710</gtr:id><gtr:title>Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/578819b768f915c051f821456e82fdd7"><gtr:id>578819b768f915c051f821456e82fdd7</gtr:id><gtr:otherNames>3C Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>5a8166fa8e7196.37201502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0621E4F4-9266-48E6-88EC-2F363672484F</gtr:id><gtr:title>Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4660e6a1d6c7ec927ecc2f6e64bb30"><gtr:id>7c4660e6a1d6c7ec927ecc2f6e64bb30</gtr:id><gtr:otherNames>Mafham MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5a8166fab03f05.49819059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F56B4122-B615-4401-911A-6CB7C333C1DB</gtr:id><gtr:title>Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5aa1058133e6e1.25827123</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2964340-6F67-44E9-AD00-A2D42C2A7F0D</gtr:id><gtr:title>Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d37509308a441b1702c956ab80fc6506"><gtr:id>d37509308a441b1702c956ab80fc6506</gtr:id><gtr:otherNames>Rocca B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>5aa00276e20784.73888399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97F9F711-F143-40D8-BEA2-75BDB16B5CF4</gtr:id><gtr:title>Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78bf4acd842867687b701ca1c29e8cd9"><gtr:id>78bf4acd842867687b701ca1c29e8cd9</gtr:id><gtr:otherNames>Staplin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5a8166fb0ba3a4.51815272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3124DCEE-0D9C-491E-9B95-18E9805D4ED3</gtr:id><gtr:title>Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.</gtr:title><gtr:parentPublicationTitle>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffd871a732200a1c7d46c59e7a29035f"><gtr:id>ffd871a732200a1c7d46c59e7a29035f</gtr:id><gtr:otherNames>Hin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0937-941X</gtr:issn><gtr:outcomeId>58be972f3dcf29.38272112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AB2FDD4-27DC-4C5B-9465-F8DB1A421C43</gtr:id><gtr:title>Impact of CKD on Household Income</gtr:title><gtr:parentPublicationTitle>Kidney International Reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262d13d32625db31cd4441acd223ed"><gtr:id>78262d13d32625db31cd4441acd223ed</gtr:id><gtr:otherNames>Morton R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa0046e405cb4.65008631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3F053A7-2D55-4B08-8AE5-927B2F4DAE27</gtr:id><gtr:title>Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3095e5f245a9b4155f07a1154b0c7ea"><gtr:id>f3095e5f245a9b4155f07a1154b0c7ea</gtr:id><gtr:otherNames>Patrono C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>5aa00b68dd4ba6.16068490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F46156C-81EC-4EB3-8715-5AB90CD2334F</gtr:id><gtr:title>Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.</gtr:title><gtr:parentPublicationTitle>BMC nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8150647508a1e4ee538bcba81440d914"><gtr:id>8150647508a1e4ee538bcba81440d914</gtr:id><gtr:otherNames>Reith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2369</gtr:issn><gtr:outcomeId>5a8166f8d8eb99.49080631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF52459A-D03F-4158-A379-ABDE32AD4E47</gtr:id><gtr:title>Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5a31e57a07e968.21406493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E02B4754-5FA8-45AE-AE70-2D167694E9B2</gtr:id><gtr:title>Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/656eab03d292fe00af58caf39a73fa54"><gtr:id>656eab03d292fe00af58caf39a73fa54</gtr:id><gtr:otherNames>Storey BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5a8166f9dab854.46523219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>546BE0DA-FBF5-4DC7-BF3B-93A3B7D53628</gtr:id><gtr:title>Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>56d962477970a9.20636585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB06204A-4E7B-4B0E-A6A7-DCF16991430B</gtr:id><gtr:title>Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81848088b320358bb7030f5adb9548f8"><gtr:id>81848088b320358bb7030f5adb9548f8</gtr:id><gtr:otherNames>UK HARP-III Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5a8166fad41091.37255171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE0CE3D0-A8A2-4558-9149-03C807308688</gtr:id><gtr:title>A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ed96360f2ef12b91e2a4190ec6c8859"><gtr:id>9ed96360f2ef12b91e2a4190ec6c8859</gtr:id><gtr:otherNames>Schlackow I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>5a8166fb365a30.56888731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>151E335B-147A-4FE9-B499-36CF737ED1B1</gtr:id><gtr:title>The Role of Emerging Risk Factors in Cardiovascular Outcomes.</gtr:title><gtr:parentPublicationTitle>Current atherosclerosis reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b78d36216cce288a182f48e403216282"><gtr:id>b78d36216cce288a182f48e403216282</gtr:id><gtr:otherNames>Lacey B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1523-3804</gtr:issn><gtr:outcomeId>5a8166f938be78.37513618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B371B0E-6B91-4DD7-81ED-A4CFFEBD01C0</gtr:id><gtr:title>Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38cc14fbd724cd8e70c0e991aa354eeb"><gtr:id>38cc14fbd724cd8e70c0e991aa354eeb</gtr:id><gtr:otherNames>Herrett E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5a8166f8549943.55698018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A3CE38A-ED6A-42FB-8915-F3F21A7FD691</gtr:id><gtr:title>Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45e1f44a10cacab8ee373d2181cc2ec7"><gtr:id>45e1f44a10cacab8ee373d2181cc2ec7</gtr:id><gtr:otherNames>Preiss D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-5061</gtr:issn><gtr:outcomeId>5aa00b1312d253.35696072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B9ACBBC-A111-4EA0-A1B4-EB8926722331</gtr:id><gtr:title>Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular quality and outcomes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5cf3906512bbd8059f3f1915040c97c"><gtr:id>d5cf3906512bbd8059f3f1915040c97c</gtr:id><gtr:otherNames>Kent S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1941-7713</gtr:issn><gtr:outcomeId>5a8166f9110219.40266185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DAD41FA-A46E-414F-814B-7596E3CC060F</gtr:id><gtr:title>Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1&amp;nbsp;Year: BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D).</gtr:title><gtr:parentPublicationTitle>Journal of the American Heart Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a5589c8a4e824c68666046341ed3a4e"><gtr:id>6a5589c8a4e824c68666046341ed3a4e</gtr:id><gtr:otherNames>Tomson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2047-9980</gtr:issn><gtr:outcomeId>5a8166f8801e81.92085830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BAA5237-BE0E-4167-8BB9-B46785186BA0</gtr:id><gtr:title>Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.</gtr:title><gtr:parentPublicationTitle>American heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9218dd9c4716dbf4af2c43fea22c5174"><gtr:id>9218dd9c4716dbf4af2c43fea22c5174</gtr:id><gtr:otherNames>REVEAL Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-8703</gtr:issn><gtr:outcomeId>5a8166f9ae1a60.94388777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10F1C47F-D159-4A27-AE3A-18F8BCF1973E</gtr:id><gtr:title>Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/113cc7e7df5287e13471822ad7fcaea6"><gtr:id>113cc7e7df5287e13471822ad7fcaea6</gtr:id><gtr:otherNames>Di Angelantonio E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5a8166f8a7fab7.50466747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE58E161-6343-4E86-8ABF-1A8328AD8803</gtr:id><gtr:title>Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78bf4acd842867687b701ca1c29e8cd9"><gtr:id>78bf4acd842867687b701ca1c29e8cd9</gtr:id><gtr:otherNames>Staplin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5aa10631547db3.11812158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FE1AF38-EB81-49F8-814D-244BACA69AD9</gtr:id><gtr:title>ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes</gtr:title><gtr:parentPublicationTitle>American Heart Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd8709e9b38dcf0cb16d5d26e22da903"><gtr:id>fd8709e9b38dcf0cb16d5d26e22da903</gtr:id><gtr:otherNames>Bowman L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a816a9145f1a7.39291657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C19AA975-A32E-4E44-8A70-FA1A345F1C16</gtr:id><gtr:title>Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e387e90297c10dfd455a0afbf134092"><gtr:id>1e387e90297c10dfd455a0afbf134092</gtr:id><gtr:otherNames>HPS3/TIMI55-REVEAL Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5a8166f9746bb1.01959405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E6C2C8C-3BB2-4C30-9136-AF9E216EFF30</gtr:id><gtr:title>Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78bf4acd842867687b701ca1c29e8cd9"><gtr:id>78bf4acd842867687b701ca1c29e8cd9</gtr:id><gtr:otherNames>Staplin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>5a8166fa652ea1.62165618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>567A17F2-A3B6-4B35-84FD-279366F8A140</gtr:id><gtr:title>Biliary Tract and Liver Complications in Polycystic Kidney Disease.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79df3f08b0a6ddac4f7998cee6e85846"><gtr:id>79df3f08b0a6ddac4f7998cee6e85846</gtr:id><gtr:otherNames>Judge PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5a8166fa1b5817.99337492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6302F69-E4BE-4B47-BBFD-C286B38EB69E</gtr:id><gtr:title>Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5aa0137e5d8df7.15848634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB7D3C8A-1FEA-4590-B7B7-6A395F238011</gtr:id><gtr:title>Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4660e6a1d6c7ec927ecc2f6e64bb30"><gtr:id>7c4660e6a1d6c7ec927ecc2f6e64bb30</gtr:id><gtr:otherNames>Mafham MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5aa106822f3650.73229888</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12026/5</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>